RUNX1 and prostate carcinoma: Interestingly, increasing evidence implicates RUNX1 in the biology and pathology of hormone-associated epithelia (Lie-A-Ling et al., 2020; Riggio and Blyth, 2017; Scheitz and Tumbar, 2013), including breast (Browne et al., 2015; Chimge et al., 2016; Ferrari et al., 2014; van Bragt et al., 2014), uterine (Planagumà et al., 2004; Planagumà et al., 2006), ovarian (Keita et al., 2013), and prostate cancers (Banach-Petrosky et al., 2007; Scheitz et al., 2012; Takayama et al., 2015).